SCHEMBL2723142

SCHEMBL2723142

COC(C)(C(=O)O)c1cccc2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
KDM4E B2RXH2 3/20 0.51
HSD17B10 Q99714 2/20 0.51
PPARG P37231 7/20 0.48
PPARA Q07869 7/20 0.48
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
PPARD Q03181 1/20 0.44
ACP3 P15309 1/20 0.44
NR4A1 P22736 1/20 0.42
NR4A2 P43354 1/20 0.42
NR4A3 Q92570 1/20 0.42
KIF11 P52732 1/20 0.42
HPGD P15428 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
RCE1 Q9Y256 1/20 0.38
PGR P06401 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29649169 1.00 ALDH1A1 (0.51) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL29697583 1.00 ALDH1A1 (0.51) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL29697568 1.00 ALDH1A1 (0.51) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL6120771 1.00 ALDH1A1 (0.51) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL12940368 1.00 ALDH1A1 (0.51) ALDH1A1KDM4EHSD17B10PPARGPPARA
Mandelic Acid SCHEMBL16689936 0.89 LMNA (0.47) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL9088372 0.85 ALDH1A1 (0.43) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL9087816 0.85 ALDH1A1 (0.43) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL9551660 0.85 ALDH1A1 (0.43) ALDH1A1KDM4EHSD17B10PPARGPPARA
SCHEMBL7945062 0.83 ALDH1A1 (0.41) ALDH1A1KDM4EHSD17B10PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1148783-A4 CONVERTING COX INHIBITION COMPOUNDS THAT ARE NOT COX-2 SELECTIVE INHIBITORS TO DERIVATIVES THAT ARE COX-2 SELECTIVE INHIBITORS UNIV VANDERBILT (US) 2003-05-21 EP claimed
EP-1148783-A1 CONVERTING COX INHIBITION COMPOUNDS THAT ARE NOT COX-2 SELECTIVE INHIBITORS TO DERIVATIVES THAT ARE COX-2 SELECTIVE INHIBITORS Vanderbilt University (US) 2001-10-31 EP claimed
WO-2000040087-A1 CONVERTING COX INHIBITION COMPOUNDS THAT ARE NOT COX-2 SELECTIVE INHIBITORS TO DERIVATIVES THAT ARE COX-2 SELECTIVE INHIBITORS VANDERBILT UNIVERSITY (US) 2000-07-13 WO claimed
EP-0380316-A2 Preparation of alpha-methylareneacetic acids SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1990-08-01 EP claimed
US-20240329525-A1 PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR MANUFACTURING CURED RELIEF PATTERN, AND SEMICONDUCTOR APPARATUS ASAHI KASEI KABUSHIKI KAISHA (JP) 2024-10-03 US disclosed
US-20240210827-A1 PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR MANUFACTURING CURED RELIEF PATTERN, AND SEMICONDUCTOR APPARATUS ASAHI KASEI KABUSHIKI KAISHA (JP) 2024-06-27 US disclosed
EP-4347836-A2 COMPOSITIONS AND METHODS FOR SILENCING CARBONIC ANHYDRASE 2 EXPRESSION Alnylam Pharmaceuticals, Inc. (US) 2024-04-10 EP disclosed
CN-113820920-B Photosensitive resin composition, method for producing cured relief pattern, and semiconductor device 旭化成株式会社 2023-07-04 CN disclosed
US-11613551-B2 Aminoglycoside derivatives and uses thereof in treating genetic disorders ELOXX PHARMACEUTICALS LTD. (IL) 2023-03-28 US disclosed
CN-110088680-B Double-layer photosensitive layer roll 旭化成株式会社 2022-12-30 CN disclosed
CN-115185157-A Photosensitive resin composition, method for producing cured relief pattern, and semiconductor device 旭化成株式会社 2022-10-14 CN disclosed
CN-114957357-A Aminoglycoside derivatives and their use in the treatment of genetic disorders ELOXX制药有限公司 2022-08-30 CN disclosed
US-6407135-B1 NITRIC OXIDE SCAVENGER COVALENTLY BONDED TO NON-STEROIDAL ANTIINFLAMMATORY AGENT OR OTHER DRUG; SIDE EFFECT REDUCTION MEDINOX, INC. 2002-06-18 US disclosed
WO-2001062085-A1 PROTECTED FORMS OF PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR MEDINOX, INC. (US) 2001-08-30 WO disclosed
US-6274627-B1 ADMINISTERING COMPOUNDS SUCH AS N-METHYL-D-GLUCAMINE DITHIO-CARBAMATE DISULFIDE FOR IN VIVO REDUCTION OF FREE RADICAL LEVELS IN A SUBJECT MEDINOX, INC. 2001-08-14 US disclosed
WO-1996025152-A1 PROCESS OF PREPARING THERAPEUTIC COMPOSITIONS CONTAINING NANOPARTICLES NANOSYSTEMS L.L.C. (US) 1996-08-22 WO disclosed
US-4672077-A Novel soluble salt having analgesic and anti-inflammatory activity, a process for the preparation thereof and pharmaceutical forms containing them ISTITUTO BIOCHIMICO PAVESE SPA (IT) 1987-06-09 US disclosed
US-4565877-A Naphthalene derivatives and method for preparation thereof TANABE SEIYAKU CO., LTD. (JP) 1986-01-21 US disclosed
EP-0107149-B1 NOVEL NAPHTHALENE DERIVATIVES AND METHOD FOR PREPARATION THEREOF Tanabe Seiyaku Co., Ltd. (JP) 1985-10-16 EP disclosed
EP-0107149-A1 Novel naphthalene derivatives and method for preparation thereof Tanabe Seiyaku Co., Ltd. (JP) 1984-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11613551-B2 Aminoglycoside derivatives and uses thereof in treating genetic disorders UPF1, AARS1, NUDT21 ALDH1A1 1473/4885KDM4E 2974/4885HSD17B10 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.